Compare · MDT vs OM
MDT vs OM
Side-by-side comparison of Medtronic plc. (MDT) and Outset Medical Inc. (OM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and OM operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $106.50B, about 1367.9x OM ($77.9M).
- Over the past year, MDT is down 7.3% and OM is down 75.8% - MDT leads by 68.5 points.
- OM has been more active in the news (4 items in the past 4 weeks vs 2 for MDT).
- MDT has more recent analyst coverage (25 ratings vs 13 for OM).
- Company
- Medtronic plc.
- Outset Medical Inc.
- Price
- $83.19-0.41%
- $4.23-3.64%
- Market cap
- $106.50B
- $77.9M
- 1M return
- +2.28%
- -4.51%
- 1Y return
- -7.27%
- -75.81%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 2
- 4
- Recent ratings
- 25
- 13
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Latest MDT
- Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
- SVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)
- New insider Thompson Kweli claimed ownership of 30,018 units of Ordinary Shares (SEC Form 3)
- SEC Form IRANNOTICE filed by Medtronic plc.
- SEC Form 10-K filed by Medtronic plc.
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey covered exercise/tax liability with 41,936 units of Ordinary Shares, decreasing direct ownership by 12% to 301,163 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 7,471 units of Ordinary Shares, decreasing direct ownership by 11% to 63,122 units (SEC Form 4)
Latest OM
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- General Counsel Brottem John L. was granted 59,830 shares, increasing direct ownership by 198% to 90,107 units (SEC Form 4)
- Chief Financial Officer Gaeta Renee was granted 71,630 shares, increasing direct ownership by 63% to 185,383 units (SEC Form 4)
- Chair and CEO Trigg Leslie was granted 99,160 shares, increasing direct ownership by 100% to 198,034 units (SEC Form 4)
- Outset Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits
- Director Hackett Patrick T was granted 10,667 shares, increasing direct ownership by 11% to 105,839 units (SEC Form 4)
- Director Oboyle Kevin C was granted 10,667 shares, increasing direct ownership by 44% to 34,785 units (SEC Form 4)
- Director Prange Karen was granted 10,667 shares, increasing direct ownership by 57% to 29,334 units (SEC Form 4)
- Director Lang Brent D. was granted 10,667 shares, increasing direct ownership by 60% to 28,518 units (SEC Form 4)
- Director Grossman D Keith was granted 10,667 shares, increasing direct ownership by 77% to 24,585 units (SEC Form 4)